Cargando…
Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art
Despite recent advances in ovarian cancer (OC) treatment, including the introduction of bevacizumab and PARP-inhibitors, OC remains a lethal disease. Other therapeutic options are being explored, such as immunotherapy (IT), which has been proved effective in many solid tumors. Findings about tumor-i...
Autores principales: | Provinciali, Nicoletta, Greppi, Marco, Pesce, Silvia, Rutigliani, Mariangela, Briata, Irene Maria, Buttiron Webber, Tania, Fava, Marianna, DeCensi, Andrea, Marcenaro, Emanuela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806340/ https://www.ncbi.nlm.nih.gov/pubmed/36601114 http://dx.doi.org/10.3389/fimmu.2022.1094017 |
Ejemplares similares
-
NK Cell-Based Immunotherapy in Colorectal Cancer
por: Della Chiesa, Mariella, et al.
Publicado: (2022) -
Taste and Smell Disorders in Cancer Treatment: Results from an Integrative Rapid Systematic Review
por: Buttiron Webber, Tania, et al.
Publicado: (2023) -
Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study
por: Paleari, Laura, et al.
Publicado: (2020) -
miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy
por: Pesce, Silvia, et al.
Publicado: (2020) -
Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment
por: Buttiron Webber, Tania, et al.
Publicado: (2021)